Market Intelligence, Clinical Progress, and High-Purity Reagents for Precision Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for MEK1/MAP2K1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Mutant Antigen Panel | MAP2K1 WT & Hotspot Mutant Recombinant Proteins (including Q56P, K57N, E203K resistance mutants). High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. | View MAP2K1 Products |
| Gene Delivery | MAP2K1 Promise-ORF / Lentivirus. Full-length ORF for stable cell line construction. | View MAP2K1 Products |
| Benchmark Ab | Anti-MAP2K1 (Phospho-Specific) Reference Clone. Recombinant positive control for Western/ELISA. | View MAP2K1 Products |
| Validator | MAP2K1 siRNA Set. For knockdown verification and assay specificity confirmation. | View MAP2K1 Products |
| Paralog Control | MAP2K2 (MEK2) Recombinant Protein. For selectivity counter-screening. >95% purity. | View MAP2K2 Products |
| Upstream Target | KRAS (G12C, G12D, WT). Combination therapy node for pathway inhibition. | View KRAS Products |
| Related Target | BRAF. Direct upstream kinase; synergistic node for melanoma and colorectal cancers. | View BRAF Products |
| Downstream Target | MAPK3 / ERK1. Feedback activation analysis and bypass resistance. | View MAPK3 Products |
Critical Assay Challenges & TarMart Advantages
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Acquired Resistance Mutant Profiling (e.g., C121S, P124L, Q56P, K57N, E203K) | Sequence Verified Mutant & WT Recombinant Proteins with >95% purity for selectivity profiling |
| Isoform Selectivity (MEK1 vs MEK2) | Homolog Panel Proteins strictly verified by mass spec for off-target counter-screening |
| Lack of Cellular Assay Controls | Full-length ORF Lentivirus for stable WT/mutant cell line generation |
| Assay Specificity & False Positives | Validated siRNA included for target knockdown verification |
| Combination Therapy Validation | Co-expression Lentivirus systems for KRAS/MEK1 dual-target cell lines |
Live MEK1 / MAP2K1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for MEK1/MAP2K1 therapeutics is intensifying, with major players shifting focus from first-generation allosteric inhibitors to next-generation combination regimens, mutant-selective modalities, and targeted protein degraders (PROTACs). As approved agents such as trametinib and cobimetinib face resistance barriers (e.g., gatekeeper mutations Q56P, K57N), the next wave of R&D is targeting acquired MEK1 mutations and upstream KRAS co-alterations through rational combination strategies. The emergence of KRAS G12C inhibitors has reinvigorated MEK1 as a critical combination node for vertical pathway blockade in colorectal and lung cancers.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Allosteric Small Molecule Inhibitor | Novartis, Roche/Exelixis, Pfizer/Array | Melanoma, NSCLC, Colorectal Cancer | WT vs Mutant Selectivity Assay (Need high-purity mutant proteins) |
| ATP-Competitive Inhibitor | AstraZeneca, Biomed Valley Discoveries | Solid Tumors (resistant settings) | Biochemical Kinase Panel (Need sequence-verified MAP2K1/MAP2K2) |
| Combination Therapy (RAF+MEK) | Novartis, Roche | BRAF-mutant Melanoma | Cellular pERK Assay (Need lentivirus-based stable cell lines) |
| Combination Therapy (KRAS+MEK) | Amgen, Mirati, Bayer | KRAS-mutant Colorectal Cancer | Pathway Panel Proteins (KRAS + MEK1 + ERK1) |
| PROTAC / Degrader | Arvinas, C4 Therapeutics | Refractory MAPK-driven cancers | Ternary Complex Formation (Need full-length ORF and benchmark antibodies) |
| Next-gen (Mutant-selective) | Array BioPharma (Pfizer) | Refractory Tumors | Mutant vs WT Selectivity Assay (Need precise mutant proteins) |